Hershey Q1 Revenue Rises 10.6% to $3.1B as Mint Sales Climb 8%
HSY•Hershey’s Ice Breakers mint and gum sales climbed 8% in Q1 as GLP-1 weight-loss drug side effects drive demand for breath fresheners. Q1 revenue rose 10.6% to $3.1B with adjusted EPS of $2.35, while full-year EPS guidance was maintained at $8.20-$8.52 per share.
1. GLP-1 Drug Trend Boosts Breath Freshener Sales
Hershey saw an 8% increase in Ice Breakers mint and gum sales during Q1, driven by adoption of GLP-1 weight-loss medications which can cause bad breath. The company cited functional snacking tailwinds as appetite suppressants limit snack portions but boost demand for oral care products.
2. Q1 2026 Financial Performance
Hershey delivered adjusted EPS of $2.35 versus a $2.04 consensus and generated $3.1 billion in revenue, up 10.6% year-over-year. Organic net sales grew 7.9% on roughly 10% pricing gains that offset a 2% volume decline, with North America Confectionery up 8.3% and Salty Snacks rising 26%.
3. Reaffirmed Full-Year Guidance
The company reiterated its fiscal 2026 adjusted EPS outlook of $8.20 to $8.52, with a midpoint of $8.36 slightly below the $8.40 consensus. Hershey expects full-year net sales to increase 4% to 5%, balancing pricing actions against input-cost pressures and supply chain efficiencies.
